The short answer
A clinically established absorption interaction between calcium supplements and oral delafloxacin was not demonstrated in the sources checked. The BAXDELA label does restrict calcium-containing solutions in the same intravenous line, but that is a different situation. Have the pharmacist check the actual oral calcium product rather than assuming the infusion warning applies to it.
What this answer covers
Oral calcium supplements with oral delafloxacin meglumine tablets. Intravenous calcium compatibility is discussed only to distinguish route; it is not evidence for an oral interaction.
- Supplement or preparation
- Calcium
- Medication ingredient
- delafloxacin
Why does calcium appear in some delafloxacin information?
The injection instructions say not to administer BAXDELA through the same line as solutions containing multivalent cations such as calcium. That is a compatibility precaution for an infusion. Swallowing a calcium tablet and receiving a calcium-containing infusion are different exposures. The injection sentence cannot establish how an oral calcium supplement affects antibiotic absorption.
What does the oral tablet label actually cover?
The oral instructions specifically identify magnesium and aluminum antacids, iron, and multivitamins with zinc or iron. They do not supply a calcium-only human study or a dedicated calcium interval. Delafloxacin tablets can be taken with or without food, which also argues against turning this evidence gap into a blanket ban on all calcium-containing meals.
What if the calcium supplement contains other minerals?
Calcium products may also contain magnesium, zinc or iron. Those additional ingredients can change which delafloxacin instruction applies. Check the complete Supplement Facts panel, including the serving size, rather than relying on calcium in the product name. Calcium citrate and carbonate should retain their distinct names even when advice is being considered at the calcium level.
How should I handle the uncertainty?
Ask the pharmacist to review the actual preparation and the antibiotic route. The available information does not justify inventing a calcium-specific percentage reduction or declaring the combination proven safe. If calcium was prescribed for a medical reason, coordinate the plan rather than stopping it solely because an infusion compatibility warning mentioned the same element.
Evidence and practical considerations
Absorption & effectiveness
A clinically established absorption interaction between calcium supplements and oral delafloxacin was not demonstrated in the sources checked. The BAXDELA label does restrict calcium-containing solutions in the same intravenous line, but that is a different situation. Have the pharmacist check the actual oral calcium product rather than assuming the infusion warning applies to it.
- Exact scope
- oral calcium supplements, exact salt and other minerals retained with oral delafloxacin meglumine tablets, 450 mg active delafloxacin equivalent
- Medication form and route
- oral
- Timing or duration
- No direct oral pair trial, dose-response or validated spacing duration established in targeted verification.
What remains uncertain
- Oral calcium is not specifically named in the label mineral list; no exact-drug oral calcium study found. Absence of evidence is not a safety clearance.
Factors that may matter: exact salt and dose; order and interval between oral doses; combination-product ingredients; oral versus nonoral route.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults prescribed oral BAXDELA tablets; injection instructions kept separate.
Take tablets at least 2 hours before or 6 hours after magnesium/aluminum antacids, iron and zinc/iron multivitamins. Patient instructions also name Mg, Al, Fe and Zn products. Tablets can be taken with or without food. Calcium/magnesium solutions are prohibited in the same IV line; that is not an oral calcium trial.
How this applies: Explicit active-moiety equivalence supports oral meglumine tablets under parent RxCUI 1927663. Oral and IV instructions are not interchangeable. Article-specific counterparty: oral calcium supplements, exact salt and other minerals retained.
No individual mineral effect size or direct oral copper/calcium trial is supplied. Label guidance is not an independent human interaction experiment.
Source 2: institutional ingredient reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: General calcium-supplement users.
Identifies calcium citrate as a common calcium supplement, less dependent on stomach acid than carbonate. Supplement Facts identifies elemental calcium.
How this applies: Supports calcium-citrate-to-calcium scope identity only. It does not itself establish a tetracycline clinical outcome. Article-specific counterparty: oral calcium supplements, exact salt and other minerals retained.
Ingredient/form information, not an exact antibiotic interaction study; digestibility does not establish lack of drug binding.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact-drug product guidance and original research checked; complete private article prepared with evidence limitations and current-claim adjudication. | |
| Research summary published |
Article revision: 1449d07e4d875a90
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.